Valuation: VISEN Pharmaceuticals

Market Cap 1.87B 2.18B 278M 241M 226M 206M 387M 26.49B 393M 2.66B 1.04B 13.26B 1.04B 1.02B 44.24B P/E 2026 *
-18.3x
P/E 2027 * -30.7x
Enterprise Value 1.61B 1.87B 239M 207M 194M 177M 333M 22.78B 338M 2.28B 892M 11.4B 896M 877M 38.04B EV / Sales 2026 *
23.8x
EV / Sales 2027 * 4.19x
Free-Float
26.93%
Yield 2026 *
-
Yield 2027 * -
1 day-0.05%
1 week+0.50%
Current month+3.74%
1 month-1.38%
3 months-16.40%
6 months-40.46%
Current year-39.09%
1 week 19.07
Extreme 19.07
20.28
1 month 18.5
Extreme 18.5
20.28
Current year 18.5
Extreme 18.5
43.3
1 year 18.5
Extreme 18.5
50
3 years 18.5
Extreme 18.5
69.15
5 years 18.5
Extreme 18.5
69.15
10 years 18.5
Extreme 18.5
69.15
Manager TitleAgeSince
Chief Executive Officer 60 07/11/2018
Director of Finance/CFO 42 13/10/2025
Chief Tech/Sci/R&D Officer 54 01/04/2020
Director TitleAgeSince
Director/Board Member 60 07/11/2018
Director/Board Member 44 08/01/2021
Director/Board Member 60 01/04/2021
Date Insider Type Main position Quantity % Market Cap.
1/1/26 Other

Chief Executive Officer

108,750 0.0955%
Change 5-day change 1-year change 3-year change Capi.($)
-0.05%+0.50%-59.14% - 278M
+1.17%+1.09%+4.03%+15.90% 48.72B
-0.58%+3.07%+465.26%+579.63% 43.99B
-0.95%+7.97%+15.80%+74.45% 40.82B
-0.48%+3.32%+26.24%+9.10% 39.79B
0.00%+6.15%+23.03%+48.00% 32.7B
-1.76%+0.26%+25.33%+120.82% 16.66B
-3.64%+0.34% - - 16.84B
+0.72%+0.31%+4.94%+21.57% 13.95B
+0.16%+7.09%+83.45%+31.09% 13.58B
Average -0.51%+3.40%+65.44%+112.57% 26.73B
Weighted average by Cap. -0.35%+3.66%+98.67%+135.82%

Financials

2026 *2027 *
Net sales 67.73M 78.81M 10.04M 8.71M 8.16M 7.44M 14M 958M 14.22M 96.09M 37.51M 480M 37.7M 36.89M 1.6B 447M 521M 66.34M 57.5M 53.9M 49.15M 92.48M 6.33B 93.96M 635M 248M 3.17B 249M 244M 10.57B
Net income -99M -115M -14.68M -12.72M -11.93M -10.88M -20.46M -1.4B -20.79M -140M -54.83M -701M -55.11M -53.91M -2.34B -58M -67.48M -8.6M -7.45M -6.99M -6.37M -11.99M -821M -12.18M -82.28M -32.12M -411M -32.29M -31.59M -1.37B
Net Debt -262M -305M -38.89M -33.71M -31.6M -28.82M -54.22M -3.71B -55.09M -372M -145M -1.86B -146M -143M -6.2B 486K 566K 72.07K 62.47K 58.56K 53.4K 100K 6.88M 102K 690K 269K 3.44M 271K 265K 11.49M
Logo VISEN Pharmaceuticals
Visen Pharmaceuticals is a holding company mainly engaged in developing and commercializing disruptive endocrine therapies. The Company's main products under development include lonapegsomatropin, navepegritide, and palopegteriparatide. The lonapegsomatropin is used to treat growth hormone deficiency in children aged 3 to 17 years old. The navepegritide is a disease repair therapy used to treat children with cartilage dysplasia aged 2 to 10 years old. The palopegteriparatide is a treatment method used to treat adult hypoparathyroidism. The Company is in the late stage of research and development, and its products are close to commercialization.
Employees
-
Date Price Change Volume
13/08/26 HK$19.98 -0.05% 93,600
12/08/26 HK$19.99 0.00% 77,800
11/08/26 HK$19.99 +0.05% 41,100
10/08/26 HK$19.98 +1.22% 68,100
07/08/26 HK$19.74 +1.13% 19,900
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
17.17CNY
Average target price
44.50CNY
Spread / Average Target
+159.15%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 2561 Stock